Crispr Therapeutics Ag (CRSP)

Cost of Revenue

$218.88M

TTM · Period ending: · USD

CRSP logo

CRSP Cost of Revenue

Latest reported$218.88M
CRSP TTM Cost of Revenue ($12.57M → $218.88M)
High-resolution chart · PNG

CRSP cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Crispr Therapeutics Ag Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
218,878,000
224,059,000
231,319,000
171,955,000
123,215,000
130,438,000
124,728,000
144,728,000
152,197,000
139,857,000
130,250,000
117,073,000
132,510,000
121,796,000
110,250,000
238,346,000
221,951,000
214,974,000
204,273,000
151,719,000
200,263,000
232,698,000
266,946,000
233,342,000
219,580,000
199,733,000
174,400,000
154,440,000
137,014,000
123,114,000
113,773,000
105,002,000
83,027,000
74,514,000
69,800,000
65,342,000
59,549,000
51,031,000
42,238,000
32,840,000
24,537,000
17,421,000
12,573,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.